This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

Dosing options – customise your patient’s treatment with Praluent® (alirocumab)

Author: Sanofi

Editorial Team

   
Praluent logo

Prescribing Information(GB)

Prescribing Information(NI)

A 4-weekly (monthly) single injection

An option for your patients who require an LDL-C reduction of >60%1

300 mg Q4W

A device you’ll recognise with one step less2,3

✅ No button to push

✅ Injection starts when device is pressed fully into the skin

✅ Designed to deliver once-monthly dose in ≤20 seconds4

Only PCSK9i with once-monthly single injection in a pre-filled pen1

✅ The potential to halve the administration days for your patients

Two twice-monthly options1

75 mg Q2W*

*Recommended starting dose.

150 mg Q2W

The usual starting dose for Praluent® is 75 mg administered subcutaneously Q2W. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg Q2W, or 300 mg Q4W (monthly), administered subcutaneously.

Customised treatment with Praluent®

Dosage information

The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.

If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.

For full instructions on use refer to the Patient information Leaflet.

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References

CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.

  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023.
  2. Praluent Patient information leaflet 150mg. March 2023.
  3. Praluent Patient information leaflet 300mg. March 2023.
  4. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.

MAT-XU-2204608 (v3.0) Date of Preparation: October 2023